2024年6月20日 · Herein, we examined the incidence of CNS relapse in patients with PMBCL treated with standard chemoimmunotherapy. This retrospective single center analysis included 154 patients with newly diagnosed PMBCL seen at Mayo Clinic. The CNS relapse rate was calculated using a competing risk model, with death considered as a competing risk.

2023年11月2日 · Central nervous system (CNS) relapse appears to be rare in patients with PMBCL, with limited literature reporting a rate of approximately 1.5% to 4%. We examined the incidence of CNS relapse, treatment approaches and …

2024年9月1日 · Keywords: ABCL, treatment-related toxicity, prognosis, overall survival (OS), LMBA02, Burkitt lymphoma ABCL-327 Anatomical Pattern of CNS Relapse in Aggressive B-cell Lymphomas Izel Okcu MD1, Jithma P Abeykoon MD1, Yucai Wang MD, .

2025年2月1日 · Herein, we examined the incidence of CNS relapse in patients with PMBCL treated with standard chemoimmunotherapy. This retrospective single center analysis included 154 patients with newly diagnosed PMBCL seen at Mayo Clinic. The CNS relapse rate was calculated using a competing risk model, with death considered as a competing risk.

PMBCL has distinct clinicopathologic features compared to diffuse large B-cell lymphoma but shares some clinical and biologic features with nodular sclerosis classic Hodgkin lymphoma (cHL). Central nervous system (CNS) relapse is exceedingly rare in cHL, therefore one may expect that CNS relapse in PMBCL is also uncommon.

Dr. Izel Okcu, is an Internal Medicine specialist practicing in Rochester, MN with undefined years of experience. including Medicare and Medicaid. New patients are welcome. Find Providers by...

At the University of Cincinnati Cancer Center, our researchers are working tirelessly to improve treatments, including Eric Vick, MD, PhD. Dr. Vick was awarded Leukemia & Lymphoma Society and ASCO...

0 Followers, 1,176 Following, 87 Posts - Izel Okcu (@izelokcu) on Instagram: "Medical Doctor Rochester, MN "

Conclusion: Key findings from this analysis include comparable survival rates in adults with BL compared to previous real-life studies, a significant and high TRM rate, and a survival benefit associated with rituximab treatment. Keywords: ABCL, treatment-related toxicity, prognosis, overall survival (OS), LMBA02, Burkitt lymphoma.